ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1603

Intervention with Methotrexate in Arthralgia at Risk for Rheumatoid Arthritis to Reduce the Development of Persistent Arthritis and Its Disease Burden (TREAT EARLIER): A Double-blind, Randomized, Placebo-controlled Trial

Doortje Krijbolder1, Marloes Verstappen1, Bastiaan van Dijk2, Yousra Dakkak1, Aleid Boer1, Yune-Jung Park1, Marianne E. de Witt-Luth3, Karen Visser4, Marc Kok5, Esmeralda T.H. Molenaar6, Pascal de Jong7, Stephan Böhringer8, Tom Huizinga1, CF Allaart1, Ellis Niemantsverdriet9 and Annette van der Helm-van Mil10, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Centre (LUMC), Leiden, Netherlands, 3Reinier de Graaf Ziekenhuis, Delft, Netherlands, 4Haga Ziekenhuis, Amsterdam, Netherlands, 5Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, 6Groene Hart Ziekenhuis, Gouda, Netherlands, 7ErasmusMC, Hendrik Ido Ambacht, Netherlands, 8Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Leiden, Netherlands, 9LUMC, Leiden, Netherlands, 10Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

Meeting: ACR Convergence 2022

Keywords: prevention, Randomized Trial, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: RA – Treatment II: Pre- and Early Disease

Session Type: Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and requires long term treatment to suppress inflammation. Currently, treatment is started when arthritis is clinically apparent. We hypothesized that earlier intervention, in the preceding phase of arthralgia and subclinical joint inflammation, prevents the development of clinical arthritis and reduces the disease burden.

Methods: In this randomised, double blind, two-year, proof-of-concept trial, adults with arthralgia clinically suspected of progressing to RA and MRI-detected subclinical joint inflammation, recruited from all rheumatology outpatient clinics in the southwest-Netherlands, were assigned (1:1) to a single intramuscular glucocorticoid-injection (120 mg) and a one-year course of oral methotrexate (up-to 25mg/week), or placebo (injection and tablets). Subsequently, participants were followed for another year. Primary endpoint was the development of clinical arthritis (fulfilling the 2010-RA-criteria or involving ≥2 joints) that persisted ≥2 weeks. Patient-reported physical functioning, symptoms and work productivity, were key secondary endpoints and measured 4-monthly. Additionally, the course of MRI-detected inflammation was studied. Two prespecified subgroup analyses were performed: analyses of participants with high-risk of developing clinical arthritis (PPV ≥70%), and analyses stratified for ACPA-status. All participants entered the intention-to-treat-analysis. The trial is registered with the Netherlands Trials Registry (NTR4853 trial NL4599).

Results: From April 16th, 2015 to September 11th, 2019, we randomly assigned 236 participants to treatment (n=119) or placebo (n=117). After 24-months, arthritis-free survival was similar in both groups (81% versus 82%, HR 0.81 (95%CI 0.45,1.48)). Physical functioning improved more in the treatment-group during the first months and remained better (mean between-group difference over two-years HAQ -0.1 (-0.2,-0.03; p=0.004). Similarly, pain (scale 0-100: -9 (-12,-4; p< 0.001), morning stiffness (-12 (-16,-8; p< 0.001), presenteeism (-8% (-13%,-3%; p=0.001) and MRI-detected joint-inflammation (-1.4 points (-2.0,-0.9; p< 0.001) showed sustained improvement compared to placebo. High-risk participants in the treatment group developed less persistent clinical arthritis during treatment (HR at 12 months 0.26 (0.07; 0.93)), but frequencies became similar at 24 months (67% in both groups). A delaying effect was also present in ACPA-positive participants. Physical functioning, pain, presenteeism and MRI-detected inflammation showed sustained treatment induced improvements in these subgroups. The number of serious adverse events was equal between the treatment groups; adverse events were as expected from methotrexate.

Conclusion: Methotrexate, the cornerstone treatment of RA, initiated at the pre-arthritis stage of symptoms and subclinical inflammation, did not prevent the development of clinical arthritis, but modified disease course as measured by sustained improvement in MRI-detected inflammation, related symptoms and impairments.

Supporting image 1


Disclosures: D. Krijbolder, None; M. Verstappen, Bristol-Myers Squibb(BMS); B. van Dijk, None; Y. Dakkak, None; A. Boer, None; Y. Park, None; M. de Witt-Luth, None; K. Visser, None; M. Kok, None; E. Molenaar, None; P. de Jong, None; S. Böhringer, None; T. Huizinga, None; C. Allaart, None; E. Niemantsverdriet, None; A. van der Helm-van Mil, None.

To cite this abstract in AMA style:

Krijbolder D, Verstappen M, van Dijk B, Dakkak Y, Boer A, Park Y, de Witt-Luth M, Visser K, Kok M, Molenaar E, de Jong P, Böhringer S, Huizinga T, Allaart C, Niemantsverdriet E, van der Helm-van Mil A. Intervention with Methotrexate in Arthralgia at Risk for Rheumatoid Arthritis to Reduce the Development of Persistent Arthritis and Its Disease Burden (TREAT EARLIER): A Double-blind, Randomized, Placebo-controlled Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/intervention-with-methotrexate-in-arthralgia-at-risk-for-rheumatoid-arthritis-to-reduce-the-development-of-persistent-arthritis-and-its-disease-burden-treat-earlier-a-double-blind-randomized-plac/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/intervention-with-methotrexate-in-arthralgia-at-risk-for-rheumatoid-arthritis-to-reduce-the-development-of-persistent-arthritis-and-its-disease-burden-treat-earlier-a-double-blind-randomized-plac/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology